INSERM U1111
INSERM U1111
Explore linked clinical trials.1 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| New Therapeutic Target for Toxic Epidermal Necrolysis (TEN) Using Anti-CD38+ Monoclonal Antibodies. | Chemically-Induced Disorders, Drug Eruptions, Drug-Related Side Effects and Adverse Reactions, Erythema, Hypersensitivity, Delayed, Skin and Connective Tissue Diseases, Stevens-Johnson syndrome, Stomatognathic Diseases, dermatitis, drug allergy, erythema multiforme, immune system disorder, mouth disorder, skin disorder, stomatitis, vesiculobullous skin disease | Not yet recruiting | Phase 1 / Phase 2 | 2025-08-07 | NCT07110662 |